Inhibrx Biosciences (INBX) Operating Leases (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Operating Leases data on file, last reported at $6.5 million in Q4 2025.

• Operating Leases for Q4 2025 came in at $6.5 million, down 19.82% year-over-year; the trailing twelve-month figure through Dec 2025 was $6.5 million (down 19.82% YoY), and the FY2025 annual result was $6.5 million, down 19.82% from the prior year.
• Operating Leases climbed to $6.5 million in Q4 2025 per INBX's latest filing, from $4.7 million in the prior quarter.
• Over five years, Operating Leases peaked at $8.0 million in Q4 2024 and troughed at $1.8 million in Q3 2024.
• A 3-year average of $5.4 million and a median of $5.9 million in 2025 frame the typical range for Operating Leases.
• On a YoY basis, Operating Leases climbed as much as 158.37% in 2025 and fell as far as 19.82% in 2025.
• A 3-year view of Operating Leases shows it stood at $3.2 million in 2023, then jumped by 153.64% to $8.0 million in 2024, then dropped by 19.82% to $6.5 million in 2025.
• Business Quant data shows INBX's Operating Leases at $6.5 million in Q4 2025, $4.7 million in Q3 2025, and $7.5 million in Q2 2025.